Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hematologic Diseases Clinical Trial

Official title:

A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03578367
• Other study ID #: CABL001E2201
• Secondary ID: 2018-001594-24
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 22, 2018
• Est. completion date: February 6, 2025

Study information

• Verified date: May 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib versus asciminib 80mg in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP)

Description:

The study is a Phase 2, multi-center, open-label, randomized study of asciminib in two different doses (40 mg or 60 mg) in combination with imatinib 400 mg versus continued imatinib versus switch to nilotinib, versus asciminib 80mg single agent in subjects with chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with imatinib first line therapy for at least one year and have not achieved deep molecular response (DMR). Eighty-four eligible subjects were randomized 1:1:1:1 to receive asciminib 60 mg once daily (QD) as add-on therapy to imatinib 400 mg QD, or 40 mg QD as add-on therapy to imatinib 400 mg QD, or to continue imatinib 400 mg QD, or to switch to nilotinib 300 mg twice a day (BID). The asciminib single agent cohort will be conducted as an open label cohort. Approximately 20 eligible subjects will be enrolled to receive asciminib 80 mg QD. Amendment 3 aims to add the asciminib single agent cohort to assess whether asciminib single agent at the recommended dose of 80mg QD leads to similar efficacy and safety as observed in the add-on arms of asciminib and imatinib. This additional cohort will help to evaluate if the combination of asciminib with imatinib is needed to increase the likelihood of achieving DMR, or if this can be achieved by asciminib alone. An interim analysis was performed to gain an early insight into the safety and efficacy of the asciminib add-on combination. The interim analysis was planned to be performed when at least 40 (50%) patients have been randomized and have been followed for their 24 weeks visit assessment or have discontinued treatment. The interim analysis cut-off was on 22-July-2020. No change in study conduct were performed based on the benefit/risk balance. The primary analysis cut-off was on 10-Jan-2022. Eighty-four patients have been randomized in the study. Subjects on the imatinib continuation arm who had not achieved MR4.5 at 48 weeks were allowed to cross-over (CO) to receive the add-on treatment within 4 weeks after week 48 visit. to receive the asciminib 60 mg combination add-on treatment, as this dose provided higher exposure. The cross-over is at the discretion of the investigator and the patient. Apart from a polymerase chain reaction (PCR) result of below MR4.5 at Week 48 visit, there are no other entry criteria for the cross-over part. Subjects on nilotinib are not allowed to cross- over to receive the add-on treatment. Subjects on the study will continue on the allocated treatment until treatment failure, intolerability, or for up to 96 weeks (in arms 1 to 4) / or 48 weeks (in asciminib single agent cohort) after the last randomized subject received the first dose of treatment. After the last dose received, every subject will be followed up for safety for 30 days.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 104
• Est. completion date: February 6, 2025
• Est. primary completion date: November 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female patients = 18 years of age with a confirmed diagnosis of Chronic Myeloid Leukemia in chronic phase (CML-CP).

2. Minimum of one year (12 calendar months) treatment with imatinib first line for CML-CP (patients have to be on imatinib 300mg or 400 mg QD at randomization For Korea only: (i)a minimum of one year (12 calendar months) of prior treatment with imatinib for patients with BCR-ABL levels > 0.1%, = 1% IS at the time of randomization. (ii) a minimum of two years (24 calendar months) of prior treatment with imatinib for patients with BCR-ABL levels > 0.01%, = 0.1% IS at the time of randomization.

3. BCR-ABL1 levels > 0.01% IS (International Scale) and = 1% IS at the time of randomization as confirmed with a central assessment at screening; patients must not have achieved deep molecular response (MR4 IS) confirmed by 2 consecutive tests at any time during prior imatinib treatment. An isolated, single test result with BCR-ABL1 levels < 0.01 % (MR4 IS) is allowed, however, it should not have been observed within the 9 months prior to randomization

4. Patient must meet the following laboratory values before randomization:

• Absolute Neutrophil Count = 1.5 x 10E9/L
• Platelets = 75 x 10E9/L
• Hemoglobin = 9 g/dL
• Serum creatinine < 1.5 mg/dL
• Total bilirubin = 1.5 x ULN (Upper Limit of Normal) except for patients with Gilbert's syndrome who may only be included with total bilirubin = 3.0 x ULN
• Aspartate transaminase (AST) = 3.0 x ULN
• Alanine transaminase (ALT) = 3.0 x ULN
• Alkaline phosphatase = 2.5 x ULN
• Serum lipase = 1.5 x ULN

5. Patients must have the following laboratory values = Lower Limit of Normal or corrected to within normal limits with supplements prior to randomization: potassium increase of up to 6.0 mmol/L is acceptable if associated with creatinine clearance within normal limits ; calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with creatinine clearance* within normal limits) ; magnesium increase up to 3.0 mg/dL or 1.23 mmol/L if associated with creatinine clearance within normal limits.

Key Exclusion Criteria:

1. Treatment failure according to European Leukemia Network (ELN) criteria 2013 during imatinib treatment.

2. Known second chronic phase of CML after previous progression to Accelerated Phase (AP)/Blast Crisis (BC).

3. Previous treatment with any tyrosine kinese inhibitors (TKIs) other than imatinib.

4. History or current diagnosis of ECG abnormalities indicating significant risk or

safety for subjects participating in the study such as:

• History of myocardial infarction, angina pectoris, coronary artery bypass graft within 6 months prior to randomization
• Concomitant clinically significant arrhythmias
• Resting QTcF = 450 msec (male) or = 460 msec (female) prior to randomization
• Long QT syndrome, family history of idiopathic sudden death or congenital long QT

syndrome, or any of the following:

• Risk factors for Torsades de Pointes
• Concomitant medications with a "known" risk of Torsades de Pointes
• inability to determine the QTcF interval

5. Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled clinically significant hyperlipidemia and high serum amylase)

6. History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis; on-going acute liver disease or history of chronic liver disease

7. History of other active malignancy within 3 years prior to randomization with the exception of basal cell skin cancer, indolent prostate cancer and carcinoma in situ treated curatively. Other protocol defined inclusion/exclusion may apply.

Related Conditions & MeSH terms

• Chronic Myelogenous Leukemia
• CML
• Hematologic Diseases
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid Chronic

Intervention

Drug:
• Asciminib add-on
Asciminib 60 mg or 40 mg taken orally once daily.
• Imatinib
Imatinib 400 mg taken orally once daily
• Nilotinib
Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
• Asciminib single agent
Asciminib 80 mg taken orally once daily

Locations

Country	Name	City	State
Austria	Novartis Investigative Site	Wien
Canada	Novartis Investigative Site	Montreal	Quebec
Czechia	Novartis Investigative Site	Brno - Bohunice
Denmark	Novartis Investigative Site	Copenhagen
France	Novartis Investigative Site	Bordeaux
Germany	Novartis Investigative Site	Dresden
Italy	Novartis Investigative Site	Milano	MI
Italy	Novartis Investigative Site	Roma	RM
Korea, Republic of	Novartis Investigative Site	Seoul	Seocho Gu
Poland	Novartis Investigative Site	Krakow
Poland	Novartis Investigative Site	Warszawa
Poland	Novartis Investigative Site	Wroclaw
Portugal	Novartis Investigative Site	Lisboa
Portugal	Novartis Investigative Site	Porto
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Saint Petersburg
Russian Federation	Novartis Investigative Site	Saint Petersburg
Spain	Novartis Investigative Site	Badalona	Catalunya
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Sevilla	Andalucia
Spain	Novartis Investigative Site	Valencia
Taiwan	Novartis Investigative Site	Changhua
Taiwan	Novartis Investigative Site	Taoyuan
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	Oxford
United Kingdom	Novartis Investigative Site	Wirral	Merseyside
United States	Georgia Regents University	Augusta	Georgia
United States	Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Austria,  Canada,  Czechia,  Denmark,  France,  Germany,  Italy,  Korea, Republic of,  Poland,  Portugal,  Russian Federation,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Molecular Response (MR)^4.5 rate between asciminib+imatinib and imatinib alone	Percentage of subjects still treated with the randomized treatment at 48 weeks and are in MR4.5 (BCR-ABL1 ratio of = 0.0032%) at 48 weeks (± assessment window), among all subjects randomized to the respective treatment arm.	at 48 weeks
Secondary	MR^4.5 rate at 48 weeks	Percentage of subjects with MR^4.5 (BCR-ABL1 ratio of = 0.0032%) at 48 weeks between asciminib+imatinib and nilotinib	at 48 weeks
Secondary	Difference in rate of MR^4.5 at 48 weeks	Difference in the percentage of subjects with MR^4.5 (BCR-ABL1 ratio of = 0.0032%) at 48 weeks between asciminib+imatinib and nilotinib	at 48 weeks
Secondary	Rate of MR^4.5 at 96 weeks	Percentage of subjects with MR^4.5 (BCR-ABL1 ratio of = 0.0032%) at 96 weeks	at 96 weeks
Secondary	Rate of MR^4.5 by 48 and 96 weeks	Best observed rate of MR^4.5 (BCR-ABL1 ratio of = 0.0032%) under randomized treatment up to the specific time point	by 48 weeks and 96 weeks
Secondary	Sustained MR^4.5 from 48 weeks until 96 weeks	Percentage of participants who are in MR^4.5 (BCR-ABL1 ratio of = 0.0032%) at 96 weeks and who have no loss of MR^4.5.	at 96 weeks
Secondary	Time to MR^4.5	Time to MR^4.5 is the time from randomization to first MR^4.5 (BCR-ABL1 ratio of = 0.0032%) computed only for subjects who achieved MR^4.5	up to 96 weeks
Secondary	Duration of MR^4.5	Time from first MR^4.5 until loss of MR^4.5 (BCR-ABL1 ratio of = 0.0032%).	end of treatment
Secondary	Incidence and severity of adverse events, changes in laboratory values, clinically notable ECG abnormalities and vital signs	To characterize the safety and tolerability profile of asciminib 60 mg or 40 mg + imatinib vs continued imatinib or switch to nilotinib or asciminib 80mg QD	end of study
Secondary	Pharmacokinetic profile of asciminib and imatinib when administered in combination - Cmax	The maximum (peak) observed drug concentration after dose administration	up to 96 weeks
Secondary	Pharmacokinetic profile of asciminib and imatinib when administered in combination - Tmax	The time to reach maximum (peak) drug concentration after dose administration	up to 96 weeks
Secondary	Pharmacokinetic profile of asciminib and imatinib when administered in combination - Cmin	Minimum drug concentration	up to 96 weeks
Secondary	Pharmacokinetic profile of asciminib and imatinib when administered in combination - AUClast	The AUC from time zero to the last measurable concentration sampling time (Tlast)	up to 96 weeks
Secondary	Pharmacokinetic profile of asciminib and imatinib when administered in combination - AUCtau	The AUC calculated to the end of a dosing interval (tau) at steady-state	up to 96 weeks
Secondary	MR^4.5 rate at 48 weeks	The percentage of subjects on asciminib 80mg QD with MR^4.5 (BCR-ABL1 ratio of = 0.0032%) at 48 weeks	at 48 weeks
Secondary	Time to MR^4.5	For subjects on asciminib 80mg QD: Time to MR^4.5 is the time from randomization to first MR^4.5 (BCR-ABL1 ratio of = 0.0032%) computed only for subjects who achieved MR^4.5	up to 48 weeks
Secondary	Duration of MR^4.5	Time from first MR^4.5 until loss of MR^4.5 (BCR-ABL1 ratio of = 0.0032%) for subjects on asciminib 80mg QD	end of treatment
Secondary	Pharmacokinetic profile of asciminib 80mg QD - Cmax	The maximum (peak) observed drug concentration after dose administration	up to 48 weeks
Secondary	Pharmacokinetic profile of asciminib 80mg QD - Tmax	The time to reach maximum (peak) drug concentration after dose administration	up to 48 weeks
Secondary	Pharmacokinetic profile of asciminib 80mg QD - Cmin	Minimum drug concentration	up to 48 weeks
Secondary	Pharmacokinetic profile of asciminib 80mg QD - AUClast	The AUC from time zero to the last measurable concentration sampling time (Tlast)	up to 48 weeks
Secondary	Pharmacokinetic profile of asciminib 80mg QD - AUCtau	The AUC calculated to the end of a dosing interval (tau) at steady-state	up to 48 weeks